Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Sulfadiazine + trimethoprim is a combination of two antibiotics used primarily in veterinary medicine to treat bacterial infections in animals, especially horses. The combination acts synergistically by inhibiting sequential steps in the bacterial folic acid synthesis pathway: sulfadiazine inhibits dihydropteroate synthase, while trimethoprim inhibits dihydrofolate reductase. This dual inhibition results in a bactericidal effect against susceptible bacteria. It is indicated for the treatment of respiratory tract infections (including pneumonia), urinary tract infections, gastrointestinal infections, wound and uterine infections, abscesses, strangles (in horses), equine protozoal myeloencephalitis (EPM), and other conditions caused by susceptible microorganisms[2][3][9]. The drug is available as oral suspensions, boluses/tablets/paste/injection for animal use.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on sulfadiazine + trimethoprim.